Skip to main content
. Author manuscript; available in PMC: 2019 Jun 3.
Published in final edited form as: Exp Cell Res. 2017 Oct 7;361(1):101–111. doi: 10.1016/j.yexcr.2017.10.007

Fig. 7. EECD34 cell fusion and differentiation is changed after modulation of retinoic acid signaling.

Fig. 7.

(A) Fusion index of EECD34 cells from mouse EOM and LEG treated with vehicle (control), retinoic acid (RA), the RAR inverse agonist BMS493 (RARinhib), or the RXR antagonist UVI 3003 (RXRinhib). (B) Percentage of desmin-positive myoblasts in EECD34 cell cultures from mouse EOM and LEG treated with vehicle (control), retinoic acid (RA), BMS493 (RARinhib), or UVI 3003 (RXRinhib). (C) Percentage of desmin-negative EECD34 cells from mouse EOM and LEG treated with vehicle (control), retinoic acid (RA), BMS493 (RARinhib), or UVI 3003 (RXRinhib). * indicates significant difference from vehicle (control). # indicates significant difference from retinoic acid (RA) treatment. ^^ indicates significant difference from EOM with the same treatment. Data are statistically significant at p ≤ 0.05.